Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic treatment shows benefits

Medtronic treatment shows benefits

7th September 2007

A dramatic reduction in pacing to the right ventricle lessens the risk of persistent atrial fibrillation in pacemaker patients, according to new research in the New England Journal of Medicine.

Medtronic reports that treatment with its Dual Chamber Minimal Ventricular Pacing Technologies reduced the relative risk of fibrillation by 40 per cent compared with conventional dual chamber pacing.

The data is based upon a study of 1,000 patients with sinus node disease, known as SAVE PACe (The Search AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction).

“This is the first study to demonstrate a clear superiority of newer forms of dual chamber pacing for sinus node disease versus older pacemaker technology,” comments Dr Michael O Sweeney, of Brigham and Women’s Hospital in Boston and lead investigator in the study.

Earlier this week Medtronic announced that it planned to take part in the 20th annual Bear Stearn healthcare conference in New York.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.